Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2018 05:30 ET | Source: Opthea Limited

Opthea Doses Patients in Europe and Israel in Phase 2b Study of OPT-302 for Wet AMD

MELBOURNE, Australia, March 27, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a developer of novel biologic therapies for the treatment of eye diseases, has dosed the first patients in Europe...
January 03, 2018 05:30 ET | Source: Opthea Limited

Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial

MELBOURNE, Australia, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases, has...
December 19, 2017 05:30 ET | Source: Opthea Limited

Opthea Doses First Patient in Phase 2b Study of OPT-302 for Wet AMD

MELBOURNE, Australia, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a developer of novel biologic therapies for the treatment of eye diseases, announced today the dosing of the first...